Hang Zhang
Sichuan University
5 Papers
Hang Zhang is an academic researcher from Sichuan University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
Yuxi Wang,Hang Zhang,Benoît Gigant,Yamei Yu,Yangping Wu,Xiangzheng Chen,Qinhuai Lai,Zhaoya Yang,Qiang Chen,Jinliang Yang +9 more
TL;DR: These studies provide a solid structural basis for developing new anti‐cancer agents for the colchicine binding site and show that the binding modes of the CBSIs were different from previous docking models, highlighting the importance of crystal structure information in structure‐based drug design.
218
Isoliquiritigenin prevents the progression of psoriasis-like symptoms by inhibiting NF-κB and proinflammatory cytokines
Yangping Wu,Xiangzheng Chen,Xiaojun Ge,Hongwei Xia,Yuxi Wang,Siyuan Su,Wenting Li,Tinghan Yang,Mingtian Wei,Hang Zhang,Lantu Gou,Jiong Li,Xian Jiang,Jinliang Yang +13 more
TL;DR: ISL exhibited anti-inflammatory effects in psoriasis models, by downregulating IL-6 and IL-8 via suppression of NF-κB activity, suggesting that ISL might serve as a potential candidate for treatment of Psoriasis and other autoimmune inflammatory diseases.
40
Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yuqin Yao,Lin Yu,Xiaolan Su,Yuxi Wang,Wenting Li,Yangpin Wu,Xiangzheng Cheng,Hang Zhang,Xian Wei,Hao Chen,Rundong Zhang,Lantu Gou,Xiaoxin Chen,Yongmei Xie,Bo Zhang,Yonghui Zhang,Jinliang Yang,Yuquan Wei +17 more
TL;DR: Three kinds of linkers were designed to connect SN-38, the bioactive metabolite of the anticancer drug irinotecan, with the anti-HER2 antibody trastuzumab to prepare three different ADC conjugates (T-SN38 A, B and C), which have great potential for HER2-positive ovarian cancer.
34
Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of colorectal cancer
Li Xu,Yuan Wang,Xing-Bing He,Yuan Gao,Frédéric Lirussi,Yi Zhou,Carmen Garrido,Hang Zhang,Tian Xie,Xiang-Yang Ye +9 more
TL;DR: Wang et al. as mentioned in this paper designed and synthesized a series of novel small-molecule inhibitors of heat shock protein 110 based on previously reported HSP110 modulator (hit 1).
3
Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
Hang Zhang,Yuxi Wang,Yangping Wu,Xiaohua Jiang,Yiran Tao,Yuqin Yao,Yujia Peng,Xiangzheng Chen,Yuyin Fu,Lin Yu,Ruixue Wang,Qinhuai Lai,Weirong Lai,Wenting Li,Yu-Huan Kang,Shuli Yi,Ying Lu,Lantu Gou,Min Wu,Jinliang Yang +19 more
TL;DR: A novel type of ADCs composed of anti-HER2 scFv–HSA fusion antibodies conjugates with a potent cytotoxic drug DM1 is effective and selective targeting to HER2-positive cancer, and may be a promising antitumor drug candidate for further studies.